Study Details

Back to Search Results

YM443 in Subjects with Functional Dyspepsia

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT00102310

Astellas Study ID

The unique identification code given by the study sponsor.

443-CL-008

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Indigestion, Nausea

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - 75 Years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2004 - Mar 2006

Masking

Not Available

Enrollment number

416

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Dose Ranging Study of YM443 in Subjects with Functional Dyspepsia

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for YM443 in Subjects with Functional Dyspepsia? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Dr. Charles Barish

Raleigh, United States, 27812

Dr. Simon Behar

Hialeah, United States, 33013

Dr. Michael Bennett

San Diego, United States, 92123

Dr. Bal Raj Bhandari

Monroe, United States, 71201

Dr. Eugene Bonapace

Great Neck, United States, 11021

Dr. Gregory Cooper

Cleveland, United States, 44106

Dr. Gurmej Dhillon

Fresno, United States, 93710

Dr. Steven Duckor

Orange, United States, 92869

Dr. Peter Eweje

Jacksonville, United States, 28546

Dr. Gary Falk

Cleveland, United States, 44195

Dr. Ramin Farsad

Encinitas, United States, 92024

Dr. Theodor Feinstat

Roseville, United States, 95661

Dr. Vitaly Fishbein

West Orange, United States, 07052

Dr. William Gramley

Wilmington, United States, 28401

Dr. Robert Fisher

Philadelphia, United States, 19140

Dr. James Grendell

Mineola, United States, 11501

Dr. Michael Grossman

Oklahoma City, United States, 73112

Dr. Robert Hardi

Chevy Chase, United States, 20815

Dr. William Harlan

Asheville, United States, 28801

Dr. Wieslaw Ignatowicz

Brooklyn, United States, 11222

Dr. Prahalad Jajodia

Fresno, United States, 93703

Dr. Suresh Karne

Huntsville, United States, 35802

Dr. Robert Kindel

Cincinnati, United States, 45220

Dr. Richard Krause

Chattanooga, United States, 37404

Dr. Braden Kuo

Boston, United States, 02114

Dr. Robert Lustig

Bridgewater, United States, 08807

Dr. Daniel Maico

Gainesville, United States, 32605

Dr. Richard McCallum

Kansas City, United States, 66160

Dr. Stephen Palte

Atlanta, United States, 30339

Dr. Daniel Pambianco

Charlottesville, United States, 22911

Dr. John Poulos

Fayetteville, United States, 28304

Dr. Rejendra Prasad Gupta

Trenton, United States, 08618

Dr. Ronald Pruitt

Nashville, United States, 37205

Dr. James Race

Dallas, United States, 75224

Dr. Dennis Riff

Anaheim, United States, 92801

Dr. Mark Ringold

Christiansburg, United States, 24073

Dr. Julio Salcedo

Washington, United States, 20010

Dr. Michael Schmalz

Milwaukee, United States, 53215

Dr. Nathan Segall

Atlanta, United States, 30342

Dr. Abbass Shafii

Colorado Springs, United States, 80909

Dr. Nayan Shah

Eynon, United States, 18403

Dr. William Snape

San Francisco, United States, 94115

Dr. Cynthia Strout

Mt. Pleasant, United States, 29464

Dr. Mark Swaim

Jackson, United States, 38305

Dr. Peter Winkle

Cypress, United States, 90630

Azazuddin Ahmed, MD

Oak Brook, United States, 60523

Brian Covey, MD

Dubuque, United States, 52001

Ralph Alhalel, MD

McAllen, United States, 78503

Wayne Schonfeld, MD

Hollywood, United States, 33021

David Dulitz, MD

Metairie, United States, 70006

Vinod Rustgi, MD

Fairfax, United States, 22031

Carroll Steinfeld, MD

Madisonville, United States, 42431

James Thrasher, MD

Little Rock, United States, 72205

Robert Smith, MD

Saluda, United States, 29138

George James, MD

Nashville, United States, 37203

Scott Levenson, MD

San Carlos, United States, 94070

Sardar Khan, MD

Houston, United States, 77090

Robert Braun, MD

Topeka, United States, 66606

Michael Mirhej, MD

Eugene, United States, 97401

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo